Literature DB >> 15865605

The multifunctional role of the immunohistochemical expression of MMP-7 in invasive breast cancer.

E Mylona1, A Kapranou, J Mavrommatis, S Markaki, A Keramopoulos, L Nakopoulou.   

Abstract

The secretion of matrix metalloproteinases (MMPs) is crucial in the metastasis of cancer cells, since MMPs are responsible for the degradation of extracellular matrix (ECM). Among them, matrix metalloproteinase-7 (MMP-7) or matrilysin 1 is a stromelysin which degrades type-IV collagen, fibronectin and laminin. Immunohistochemistry was performed to detect MMP-7 protein in infiltrative breast carcinomas. MMP-7 was studied along with clinicopathological parameters, disease-free and overall survival, and p53, c-erbB-2, topoIIa, MMP-2, uPAR and beta-catenin. MMP-7 immunoreactivity was detected in the cytoplasm of cancer cells in 54.2% (96/177) and tumor stromal cells in 47.5% (84/177), as well as in normal epithelium adjacent to malignant epithelium. MMP-7 reactivity in cancer cells displayed an inverse association with nuclear grade (p=0.049) and topoIIa (p=0.03). A parallel association was observed between the expression of MMP-7 in both malignant and stromal cells with uPAR in cancer cells (p=0.033 and p=0.027, respectively). MMP-7 of tumor stromal cells depicted a parallel correlation with MMP-2 of the same cell type (p=0.044), while abnormal beta-catenin expression was inversely associated with MMP-7 of cancer cells (p=0.047). Our results show the multifunctional role of MMP-7 in the mammary gland, since it seems to be associated with a less aggressive phenotype, while, at the same time, being involved in invasion, through its collaboration with indicators of invasion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15865605     DOI: 10.1111/j.1600-0463.2005.apm_02.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  7 in total

1.  A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression.

Authors:  Giuseppe Pelosi; Aldo Scarpa; Giulia Veronesi; Lorenzo Spaggiari; Barbara Del Curto; Patrick S Moore; Patrick Maisonneuve; Angelica Sonzogni; Michele Masullo; Giuseppe Viale
Journal:  Virchows Arch       Date:  2005-09-13       Impact factor: 4.064

2.  Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background.

Authors:  Michelle D Martin; Kathy J Carter; Sharon R Jean-Philippe; Mayland Chang; Shahriar Mobashery; Sophie Thiolloy; Conor C Lynch; Lynn M Matrisian; Barbara Fingleton
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  Genetic polymorphisms in the MMP-7 gene and breast cancer survival.

Authors:  Alicia Beeghly-Fadiel; Xiao-Ou Shu; Jirong Long; Chun Li; Qiuyin Cai; Hui Cai; Yu-Tang Gao; Wei Zheng
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

4.  Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma.

Authors:  Teijiro Hirashita; Yukio Iwashita; Masayuki Ohta; Yoko Komori; Hidetoshi Eguchi; Kazuhiro Yada; Seigo Kitano
Journal:  J Gastrointest Surg       Date:  2012-01-13       Impact factor: 3.452

5.  Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation.

Authors:  N Voorzanger-Rousselot; F Juillet; E Mareau; J Zimmermann; T Kalebic; P Garnero
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

6.  Clinicopathological significance of matrix metalloproteinase-7 protein expression in esophageal cancer: a meta-analysis.

Authors:  Shuai Miao; Shi-Yao Zhou; Chun-Shan Han; Le-Ning Zhang; Hong-Bin Sun; Bin Yang
Journal:  Drug Des Devel Ther       Date:  2015-07-20       Impact factor: 4.162

7.  Prognostic significance of GAD1 overexpression in patients with resected lung adenocarcinoma.

Authors:  Mitsuhiro Tsuboi; Kazuya Kondo; Kiyoshi Masuda; Shoichiro Tange; Koichiro Kajiura; Tomohiro Kohmoto; Hiromitsu Takizawa; Issei Imoto; Akira Tangoku
Journal:  Cancer Med       Date:  2019-06-17       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.